Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
Status:
Recruiting
Trial end date:
2024-06-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment
regimen of anifrolumab versus placebo in Asian participants with active systemic lupus
erythematosus (SLE).